Takgen

Takgen is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the discovery and development of innovative biologics for cancer treatment. The company utilizes its proprietary antibody engineering platforms to create a pipeline of monoclonal antibodies, bispecific antibodies, and multi-functional fusion proteins. Its lead candidate, T001, is a high-affinity antibody targeting Claudin 18.2 for the treatment of gastric and pancreatic cancers. Takgen's strategy focuses on modulating the tumor microenvironment and enhancing immune responses to overcome resistance in solid tumors. The company is led by a team of industry veterans with extensive experience in antibody drug discovery and clinical development. Through strategic R&D, Takgen aims to deliver next-generation immunotherapies that provide significant clinical benefits over existing standards of care.